Future Directions in Precision Medicine: An Evolving Treatment Landscape
Closing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.
Role of a Pharmacist in Developing Treatment Pathways and Educating Patients
Ryan Haumschild, PharmD, MS, MBA, reflects on how oncologic pharmacists can help to develop treatment pathways and educate patients on precision medicine.
Role of a Pharmacist in the Multidisciplinary Approach to Identifying Biomarkers
Expert perspectives on the role of an oncologic pharmacist within a tumor board and how they can improve upon precision medicine in cancer management.
The Value of Molecular Tumor Boards and Multidisciplinary Care
Comprehensive discussion on the role of tumor boards—or more specifically, molecular tumor boards—in the optimal management of patients with cancer.
Improving Uptake of Biomarker Testing and Precision Medicine in Cancer Care
Key opinion leaders in the field of cancer management discuss resistance to the uptake of biomarker testing and precision medicine, with deference to the community setting.
Optimizing the Timing and Utilization of Biomarker Testing in Cancer Care
Expert pathologist Samuel K. Caughron, MD, FCAP, shares best strategies for the timing and utilization of biomarker testing while managing patients with cancer.
Updating Biomarker Testing Strategies as Cancer Care Evolves
Timothy J. Pluard, MD; Ossama Tawfik, MD; and Sujith R. Kalmadi, MD, reflect on how they update their biomarker testing strategies as the field of cancer care and precision medicine evolves.
Armamentarium of Biomarker Testing Strategies in Cancer Care
Expert perspectives on the wide array of biomarker testing modalities available to patients receiving treatment for cancer.
Optimizing Cancer Care: Interpreting and Communicating Biomarker Testing Results
Comprehensive discussion on how best to interpret and document results from biomarker testing, along with considerations for communicating results with other healthcare professionals.
Addressing Barriers to Adequate Biomarker Testing in Cancer Care
Key opinion leaders highlight challenges to adequate biomarker testing in cancer care and consider the value of collaboration to overcome these barriers.
Targetable Mutations Found in Breast Cancers
Shared insight on key driver mutations and corresponding precision medicine in the setting of breast cancer management.
Targetable Mutations and Rearrangements in Lung Cancers
Expert participants share their perspective on the advent of precision medicine in lung cancer, following the discovery of several key driver mutations and alterations.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512